Sign in

ACUT on OTC

Accustem Sciences Inc.

Accustem Sciences Inc. is an American pharmaceutical preparations company, incorporated in Delaware.1 It is headquartered in New York, New York.1 Its shares trade on OTC under the symbol ACUT.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerACUT on OTC1
  • IndustryPharmaceutical Preparations1
  • HeadquartersNew York, New York1
  • Incorporated inDE2
  • Business address5 Penn Plaza, 19Th Floor, #1954, New York, Ny 100012
  • Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company2

See how the biggest companies compare on our leaderboards

Accounting Oversight Board regarding the communication of critical audit matters in the auditor’s report on financial statements.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income4567-$1.8M in 2025+162% since 2021
-$4.0M-$3.0M-$2.0M-$1.0M02021: -$670.6K-$670.6K20212022: -$3.7M-$3.7M2022+459%2023: -$2.1M-$2.1M2023−45%2024: -$1.5M-$1.5M2024−27%2025: -$1.8M-$1.8M2025+17%
Net income4567-$1.8M in 2025+162% since 2021
-$4.0M-$3.0M-$2.0M-$1.0M02021: -$670.6K-$670.6K20212022: -$3.7M-$3.7M2022+459%2023: -$2.1M-$2.1M2023−45%2024: -$1.5M-$1.5M2024−27%2025: -$1.8M-$1.8M2025+17%

Every line of the income statement as filed: the last 2 fiscal years, latest first.7

Period ending2025-12-312024-12-31
Research and development expenses$281.0K$138.3K
General and administrative expenses$1.5M$1.4M
Total operating expenses$1.8M$1.5M
LOSS FROM OPERATIONS-$1.8M-$1.5M
LOSS, BEFORE INCOME TAX-$1.8M-$1.5M
NET LOSS-$1.8M-$1.5M
Net loss per share attributable to common shareholders, basic-$0.12-$0.13
Net loss per share attributable to common shareholders, diluted-$0.12-$0.13
Weighted average common shares outstanding used in computing net loss per share attributable to common shareholders, basic15.2M shares11.4M shares
Weighted average common shares outstanding used in computing net loss per share attributable to common shareholders, diluted15.2M shares11.4M shares

Compare Accustem Sciences Inc. with another company

What it owns

What Accustem Sciences Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$11.0K7 Dec 31, 2025$11.0K7 Dec 31, 20240%
Accumulated depreciation$11.0K7 Dec 31, 2025$10.6K7 Dec 31, 2024+4.0%
Property and equipment, net$4187 Dec 31, 2024$4.0K6 Dec 31, 2023−89.7%

Properties, in its own words

We do not own any property but utilize approximately 75 square feet of office space in London from Tiziana for which we reimburse Tiziana at cost through a shared services agreement. We believe that our existing facilities are adequate to meet our current needs for the foreseeable future, and that suitable additional alternative spaces will be available in the future on commercially reasonable terms if needed.

Item 2 of the 10-K filed Apr 14, 2026.3

Leadership

Who has led Accustem Sciences Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Wendy E. Blosser2022

Chief financial officer

  1. Keeren Shah2021
2025
Board members and other officers (4)

Former names

  • AccuStem Sciences LtdMar 12, 2021 to Jul 1, 20212

Timeline

  1. Nov 26, 20258-K Other events15
  2. Jan 2, 20258-K Change of auditor16
  3. Dec 30, 20248-K Change of auditor17
  4. Apr 10, 20248-K Change of auditor18
  5. Jun 9, 20238-K Executive or director change19
  6. Jun 7, 20238-K Regulation FD disclosure20
  7. Nov 16, 20228-K Executive or director change21
  8. Oct 14, 20228-K Shareholder vote22
  9. Jun 21, 20228-K Executive or director change23
  10. May 27, 2022New chief executive Wendy E. Blosser becomes CEO10
  11. Apr 5, 20228-K Entered a material agreement; Unregistered sale of shares; Executive or director change24
  12. Mar 10, 20228-K Executive or director change25
  13. Dec 3, 20218-K Entered a material agreement; Completed an acquisition or sale; Unregistered sale of shares26

Filings

64 filings to the SEC since October 2021: 6 annual reports, 14 quarterly reports, 12 major events, 17 insider forms, 15 other. The latest 20:

  1. Aug 14, 202610-Q EDGAR
  2. May 15, 202610-Q EDGAR
  3. Apr 14, 202610-K EDGAR
  4. Mar 31, 2026NT 10-K EDGAR
  5. Nov 26, 20258-K EDGAR
  6. Nov 12, 202510-Q EDGAR
  7. Aug 14, 202510-Q EDGAR
  8. Jun 16, 20254 EDGAR
  9. Jun 13, 20254 EDGAR
  10. May 20, 202510-Q EDGAR
  11. May 15, 2025NT 10-Q EDGAR
  12. Apr 10, 20254 EDGAR
  13. Apr 8, 20254 EDGAR
  14. Apr 3, 202510-K EDGAR
  15. Mar 31, 2025NT 10-K EDGAR
  16. Feb 21, 2025SEC STAFF ACTION EDGAR
  17. Jan 3, 20254 EDGAR
  18. Jan 2, 20258-K/A EDGAR
  19. Dec 30, 20248-K EDGAR
  20. Nov 18, 202410-Q EDGAR

The 64 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

15 open-market trades by officers, directors and large owners since October 2021: 15 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jun 13, 2025CERRONE GABRIELE MDirectorBuy2,400$1.02$2.4KForm 4
Jun 12, 2025CERRONE GABRIELE MDirectorBuy8,991$0.83$7.5KForm 4
Jun 11, 2025CERRONE GABRIELE MDirectorBuy28,205$0.39$11.0KForm 4
Apr 9, 2025CERRONE GABRIELE MDirectorBuy3,000$0.67$2.0KForm 4
Apr 8, 2025CERRONE GABRIELE MDirectorBuy35,000$0.67$23.4KForm 4
Apr 7, 2025CERRONE GABRIELE MDirectorBuy52,802$0.64$33.6KForm 4
Mar 18, 2025CERRONE GABRIELE MDirectorBuy100,000$0.45$45.0KForm 4
Dec 31, 2024CERRONE GABRIELE MDirectorBuy100,000$0.38$38.0KForm 4
Dec 30, 2022CERRONE GABRIELE MDirectorBuy5,000$1.40$7.0KForm 4
Dec 2, 2022CERRONE GABRIELE MDirectorBuy3,729$1.42$5.3KForm 4
Nov 18, 2022CERRONE GABRIELE MDirectorBuy24,500$1.05$25.7KForm 4
Aug 1, 2022CERRONE GABRIELE MDirectorBuy10,000$0.79$7.9KForm 4
Jun 8, 2022CERRONE GABRIELE MDirectorBuy20,000$0.50$10.0KForm 4
Apr 26, 2022CERRONE GABRIELE MDirectorBuy5,266$1.49$7.8KForm 4
Apr 25, 2022CERRONE GABRIELE MDirectorBuy4,181$1.35$5.6KForm 4

From Forms 4 filed with the SEC.

SEC filer profile

How Accustem Sciences Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARAccustem Sciences Inc.1
  • CIK0001850767
  • Employer ID (EIN)87-37744383
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; a shell company3
  • Incorporated inDelaware3
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address5 Penn Plaza, 19Th Floor, #1954, New York, NY 100011
  • Phone4420706610001
  • Shares outstanding16,072,267 as of Aug 14, 20268
  • Public float$9.7M as of Jun 30, 20253
  • AuditorMercurius & Associates LLP, New Delhi, India PCAOB ID 3223; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceMar 12, 20211
  • Filings76 in all: 10-Q (14), 4 (11), 8-K (11), 3 (6), 10-K (5), NT 10-Q (5), UPLOAD (4), NT 10-K (3)1
    All 22 form types

    20FR12G/A (2), CORRESP (2), SEC STAFF ACTION (2), 10-K/A (1), 20FR12G (1), 8-K/A (1), DEF 14A (1), DEFA14A (1), DRS (1), EFFECT (1), F-6 (1), PRE 14A (1), S-1 (1), S-1/A (1)

  • Latest filingsAnnual report (10-K) Apr 14, 2026
    Quarterly report (10-Q) Aug 14, 2026
    Proxy statement (DEF 14A) Sep 14, 2022
    Latest 8-K (8-K) Nov 26, 2025

Securities registered for trading

ClassSymbolExchange
Common StockACUT

From the cover page of the 10-K filed Apr 14, 2026 (Section 12(b) of the Exchange Act).3

Risk factors and legal proceedings

The risks Accustem Sciences Inc. names in Item 1A of its 10-K filed Apr 14, 2026: 58 risks under these headings, as written.3

  • Risks Specific to the Development of the Business
  • We do not have collaborations in place with institutions for utility studies and there is no guarantee that we will be able to demonstrate prospective clinical utility of MSC or StemPrintER.
  • There are risks associated with the process of establishing a CLIA laboratory and in offering MSC or StemPrintER which are outside our control.
  • We will be dependent on third parties to provide certain resources and services to us, as we have limited resources
  • We are subject to research and product development risk
  • We are subject to risks associated with medical and technological change and obsolescence
  • Risks Relating to Intellectual Property
  • Our rights to develop and commercialize our product candidates are subject to the terms and conditions of licenses granted to us by others. If we fail to comply with our obligations under our existing and any future intellectual property licenses with third parties, we could lose license rights that are important to our business.
  • If we are unable to obtain and maintain patent protection for our product candidates and technology, or if the scope of our patent protection is not sufficiently broad, our competitors could develop and commercialize similar products and technology
  • Our intellectual property is open to challenge
  • Our strategy involves generating commercially valuable intellectual property that can be protected
  • Market and Competitive Risks
The other 50 risks
  • We operate in a competitive market and will face competition from competitors involved in genetic, genomic and/or biomarker testing of patients with or at risk of cancer
  • The market opportunities for our product candidates may be smaller than we anticipate
  • The future commercial success of our product candidates will depend upon the degree of each product candidate’s market acceptance by physicians, patients, third-party payors and others in the medical community
  • The insurance coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for our approved product candidates could limit our ability to market those products
  • Regulatory Risks
  • Complying with numerous regulations pertaining to our business is an expensive and time-consuming process, and any failure to comply could result in substantial penalties.
  • If we fail to comply with healthcare laws and regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected.
  • Our products and operations are subject to extensive government regulation and oversight both in the United States and abroad, and our failure to comply with applicable requirements could harm our business.
  • The FDA may modify its enforcement discretion policy with respect to laboratory developed tests, or LDTs, in a risk-based manner, and we may become subject to extensive regulatory requirements and may be required to conduct additional clinical trials prior to continuing to sell our existing tests or launching any other tests in the United States we may develop, which may increase the cost of conducting, or otherwise harm, our business.
  • If we do not obtain and maintain any required international regulatory registrations and marketing authorizations or certifications for our products, we will be unable to market and sell such products outside of the United States.
  • Legislative or regulatory reforms in the United States or the EU may make it more difficult and costly for us to obtain marketing authorizations or certifications for any product candidate or to manufacture, market or distribute any product candidates after such authorizations have been obtained.
  • Changes in funding for, or disruptions caused by global health concerns impacting, the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new medical device products from being developed, authorized or commercialized in a timely manner, which could negatively impact our business.
  • If we are unable to effectively adapt to changes in the healthcare industry, including changes to laws and regulations regarding or affecting the U.S. healthcare reform, our business may be harmed.
  • Our failure to maintain compliance of our future clinical laboratory operations with applicable laws could result in substantial civil or criminal penalties
  • Failure in, or security breaches or incidents impacting, our information technology, storage systems or our clinical laboratory equipment could significantly disrupt our operations and our research and development efforts.
  • Potential conflicts of interest between our management, Board of Directors, and significant stockholders and Tiziana could result in a divergence of interest between management and investors.
  • Certain members of our management do not devote their full time to our company and certain of our officers and directors may have conflicts of interest.
  • Risks Specific to Our Financial Position and the Future Financing of the Business
  • We have incurred net losses in every year since our inception. We anticipate that we will continue to incur losses for the foreseeable future and may never achieve or maintain profitability.
  • We need substantial additional funding to complete the development of its product candidates, which may not be available on acceptable terms, if at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate certain of our product development, research operations or future commercialization efforts, if any
  • Our financial condition and operating results have varied significantly in the past and losses are continuing and increasing due to a variety of factors, many of which are beyond our control.
  • Our recurring losses from operations raise substantial doubt about our ability to continue as a going concern
  • Risks Related to our Business Operations
  • Risks relating to managing growth, employee matters and other risks relating to our business
  • Challenges in identifying and retaining key personnel could impair our ability to conduct and grow our operations effectively
  • We are reliant upon the expertise and continued service of a small number of key individuals of our management, Board of Directors and scientific advisors
  • We may become subject to product liability claims
  • Market and economic conditions may negatively impact our business, financial condition and share price.
  • Clinical trials are expensive, time-consuming, and may not be successful.
  • If testing of a particular diagnostic test or product candidate does not yield successful results, then we will be unable to commercialize that test or product candidate.
  • Even if our diagnostic tests or product candidates receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, third-party payers and others in the medical community necessary for commercial success.
  • If we are unable to establish effective sales, marketing, and distribution capabilities or enter into agreements with third parties with such capabilities, we may not be successful in commercializing our diagnostic tests or product candidates if and when they are approved.
  • If we are unable to convince physicians as to the benefits of our proposed diagnostic tests or product candidates, we may incur delays or additional expense in our attempt to establish market acceptance.
  • We face substantial competition, which may result in others discovering, developing, or commercializing competing diagnostic tests or products before or more successfully than we do.
  • If users of our proposed diagnostic tests or products are unable to obtain adequate reimbursement from third-party payers or governmental agencies or if new restrictive legislation is adopted, market acceptance of our proposed tests or products may be limited, and we may not achieve revenues.
  • Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.
  • The market for our proposed tests and products is competitive and rapidly changing, and new diagnostic technologies which may be developed by others could impair our ability to maintain and grow our business and remain competitive.
  • Risks Related to Our Reliance on Third Parties
  • We rely, and expect to continue to rely, on third parties to conduct our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates.
  • Our failure to find third party collaborators to assist or share in the costs of product development could materially harm our business, financial condition and results of operations.
  • Risks Related to Commercialization of Our Product Candidates
  • Even if we are successful in completing all pre-clinical studies and clinical trials, we may not be successful in commercializing one or more of our product candidates.
  • Risks Related to Our Common Stock
  • Further issuances of Common Shares may be dilutive
  • Economic conditions and current economic weakness
  • We presently do not intend to pay cash dividends on our common stock.
  • Our principal shareholder has a significant holding in the company which may give them influence in certain matters requiring approval by shareholders, including approval of significant corporate transactions in certain circumstances
  • We are an “emerging growth company”, and there are reduced disclosure requirements applicable to emerging growth companies
  • Our internal computer systems, or those of our collaborators or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs.
  • Significant disruptions of information technology systems or breaches of data security could adversely affect our business.
  • We will incur increased costs as a result of operating as a U.S. public company, and our management will be required to devote substantial time to new compliance initiatives
  • If we are unable to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, shareholders could lose confidence in our financial and other public reporting, which would harm our business
  • Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud
  • Future changes to tax laws could materially adversely affect our company and reduce net returns to our shareholders
  • Trading on the OTC Markets may be volatile and sporadic, which could depress the market price of our common stock and make it difficult for our stockholders to resell their shares.
  • Climate change initiatives could materially and adversely affect our business, financial condition, and results of operations.

Legal proceedings

We are not party to any material legal matters or claims. In the future, we may become party to legal matters and claims arising in the ordinary course of business, the resolution of which we do not anticipate would have a material adverse impact on our financial position, results of operations or cash flows.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
    SEC EDGAROther events
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26